News & Updates
Showing Multidisciplinary articles
Showing

Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O2 support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study

Pioglitazone boosts HbA1c decrease while preventing ketone increase
In patients with type 1 diabetes (T1D) treated with SGLT2 inhibitors, such as dapagliflozin, the addition of pioglitazone helps to intensify the reduction in HbA1c and blocks the increase in plasma ketone driven by SGLT2 inhibitors, reports a study presented at ADA 2024. This enables long-term cardiovascular and renal outcome studies to be safely performed in T1D patients.

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.





